Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 31.3% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in diabetes management solutions, including insulin pumps and related technologies. The stock had a strong bullish movement today, with shares surging significantly.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 31.3% on Feb 20, 2026 20:40

• Adjusting Tandem Diabetes Care's price target upwards and maintaining a Hold rating likely contributed to investor optimism and buying interest in the stock.
• Tandem Diabetes Care's record-setting Q4 and full-year 2025 financial performance, surpassing $1 billion in sales, and achieving double-digit growth with improved profitability, showcased the company's strong fundamentals and growth potential.
• The strategic shift towards a "pay-as-you-go" reimbursement structure in the U.S. pharmacy channel, despite near-term revenue headwinds, signals a long-term focus on market expansion and profitability, which could have positively influenced investor sentiment.
• The introduction of new technologies like Control-IQ+ and Mobi Tubeless, along with strong financial results and optimistic 2026 guidance, likely fueled investor confidence and contributed to the significant bullish movement in Tandem Diabetes Care's stock price.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Truist Securities Adjusts Tandem Diabetes Care Price Target to $27 From $24, Maintains Hold Rating

Truist Securities has increased its price target for Tandem Diabetes Care (TNDM) from $24 to $27, while reiterating a Hold rating on the stock. This adjustment comes amidst other analyst actions for the company, including UBS maintaining a Neutral rating with an adjusted price target of $22 from $17. The article also provides recent news on Tandem Diabetes Care's financial performance, including a Q4 loss and increased sales, and operational updates.

https://www.marketscreener.com/news/truist-securities-adjusts-tandem-diabetes-care-price-target-to-27-from-24-maintains-hold-rating-ce7e5dddde81f025

Tandem Diabetes Care Inc (TNDM) Shares Up 32.47% on Feb 20

Shares of Tandem Diabetes Care Inc (TNDM) surged 32.47% in mid-day trading on February 20, reaching an intraday high of $25.05. The stock closed at $24.44, significantly above its previous close and 144.89% above its 52-week low. Analyst forecasts suggest an average target price of $25.50, with GuruFocus estimating a fair value of $39.74.

https://www.gurufocus.com/news/8637249/tandem-diabetes-care-inc-tndm-shares-up-3247-on-feb-20

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q4 2025 Earnings Call Transcript

Tandem Diabetes Care (NASDAQ: TNDM) reported a record-setting Q4 and full-year 2025, surpassing $1 billion in sales and achieving double-digit growth with improved profitability. The company is actively modernizing commercial operations, expanding internationally, and introducing new technologies like Control-IQ+ and Mobi Tubeless. A significant strategic shift involves transitioning to a "pay-as-you-go" reimbursement structure in the pharmacy channel for the U.S. market, aiming to boost market expansion and long-term profitability despite facing near-term revenue headwinds in 2026.

https://www.insidermonkey.com/blog/tandem-diabetes-care-inc-nasdaqtndm-q4-2025-earnings-call-transcript-1699769/

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance

Tandem Diabetes Care reported record financial results for Q4 and full-year 2025, surpassing $1 billion in worldwide sales. The company achieved significant operational improvements, including a 58% gross margin in Q4, and introduced new technologies like the Android mobile control for Tandem Mobi. Looking ahead to 2026, Tandem Diabetes Care expects continued sales growth with new pay-as-you-go pharmacy structures in the U.S. and further international expansion.

https://www.biospace.com/press-releases/tandem-diabetes-care-announces-fourth-quarter-and-full-year-2025-financial-results-and-2026-financial-guidance

Tandem Diabetes Care Q4 2025 Financial Report & Revenue Growth | 2026 - News and Statistics

Tandem Diabetes Care exceeded revenue expectations in Q4 2025, reporting sales of $290.4 million, a 15% increase year-over-year, and a GAAP EPS loss of $0.01, significantly better than projected. The company achieved over $1 billion in worldwide sales for 2025 and improved its operating margin to 2.9%. Analysts project an 8.4% revenue growth for the company over the next 12 months.

https://www.indexbox.io/blog/tandem-diabetes-care-q4-2025-results-revenue-beats-estimates/

Trending Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.4% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 31.3% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 6.1% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 5.1% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.3% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 9.8% Today

Corning Incorporated ($GLW) Stock Forecast: Up 5.8% Today

Chemours Company (The) ($CC) Stock Forecast: Down 18.3% Today

Oracle Corporation ($ORCL) Stock Forecast: Down 5.2% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Down 5.2% Today

Tandem Diabetes Care, Inc. Price History

21.00.2026 - TNDM Stock was up 5.1%

• TNDM's stock price has increased by 36.3% in the last three months despite previous declines, which likely contributed to today's positive movement.
• An inquiry into potential securities claims against TNDM and concerns about misleading business information may have led to an initial stock price drop. However, today's market response suggests growing confidence in the company's future.
• Issues with certain t:slim X2 insulin pumps resulted in a significant stock decrease, causing investor unease. The subsequent recovery indicates a reevaluation of the pumps' impact on TNDM's performance.
• Analysts considering TNDM undervalued and providing fair value estimates based on projected growth and product advancements possibly influenced today's bullish activity, reflecting investor optimism about the company's future prospects.

20.01.2026 - TNDM Stock was up 31.3%

• Adjusting Tandem Diabetes Care's price target upwards and maintaining a Hold rating likely contributed to investor optimism and buying interest in the stock.
• Tandem Diabetes Care's record-setting Q4 and full-year 2025 financial performance, surpassing $1 billion in sales, and achieving double-digit growth with improved profitability, showcased the company's strong fundamentals and growth potential.
• The strategic shift towards a "pay-as-you-go" reimbursement structure in the U.S. pharmacy channel, despite near-term revenue headwinds, signals a long-term focus on market expansion and profitability, which could have positively influenced investor sentiment.
• The introduction of new technologies like Control-IQ+ and Mobi Tubeless, along with strong financial results and optimistic 2026 guidance, likely fueled investor confidence and contributed to the significant bullish movement in Tandem Diabetes Care's stock price.

30.00.2026 - TNDM Stock was up 6.0%

• The positive movement in TNDM is attributed to an improved growth outlook and strong Q4 results, as indicated in an investor letter by Meridian Growth Fund.
• Despite facing a legal investigation related to a voluntary correction for its insulin pumps, TNDM is seen as undervalued, sparking investor interest in the stock.
• An article raising concerns about weak sales volumes and declining ROIC might have initially impacted the stock negatively, but overall optimism about growth prospects and product advancements likely drove the bullish movement.
• Investors are focusing on TNDM's growth potential in the diabetes care market and product innovations, disregarding short-term challenges, which has driven the stock price higher.

20.01.2026 - TNDM Stock was up 19.0%

• Tandem Diabetes Care outperformed revenue expectations in Q4 2025 with a 15% increase year-over-year and a GAAP EPS loss of $0.01, surpassing projections. This strong financial performance is believed to have fueled the stock's bullish movement.
• Despite providing cautious 2026 sales guidance due to challenges from new business models, investors are optimistic about the company's strategic repositioning and improved profitability forecasts for 2027 and beyond, resulting in an increase in the stock's value in after-hours trading.
• The company's robust Q4 results, which exceeded revenue and EPS forecasts, coupled with positive future profitability prospects, likely bolstered investor confidence and led to the stock's upward trajectory.
• Tandem Diabetes Care's ability to beat revenue expectations, enhance operating margin, and achieve over $1 billion in global sales for 2025 demonstrates its strength and growth potential, which probably attracted investors and contributed to the favorable market movement.

20.01.2026 - TNDM Stock was up 39.4%

• Following the release of its Q4 2025 earnings report, Tandem Diabetes Care (TNDM) saw a strong bullish movement, with record-setting sales surpassing $1 billion and double-digit growth.
• Positive market response was observed towards TNDM's enhanced profitability, operational improvements, and the launch of new technologies like Control-IQ+ and Mobi Tubeless, reflecting investor confidence in the company's strategic direction.
• Despite issuing cautious sales guidance for 2026 due to transitional challenges from new business models, investors displayed optimism in TNDM's potential long-term profitability, leading to a rise in the stock price during after-hours trading.
• TNDM's ability to surpass revenue projections, enhance operating margins, and anticipate ongoing sales growth, particularly with the introduction of new pay-as-you-go pharmacy structures, contributed to the optimistic sentiment surrounding the stock.

13.00.2026 - TNDM Stock was down 5.1%

• Despite reporting a loss in Q3, Tandem Diabetes Care surpassed revenue expectations, showcasing resilience amid market challenges. The wider loss possibly influenced the downturn in the stock price.
• Speculation surrounding the forthcoming Q4 earnings report, which is anticipated to show a revenue decrease and increased loss, might have impacted the stock negatively.
• Investor concern persists regarding Tandem Diabetes Care's struggle with profitability, awaiting the company's future guidance and growth strategies following the Q4 financial results disclosure.
• The market's response to the news of the upcoming financial results release on February 19, 2026, potentially prompted profit-taking and selling activity, driving the bearish trend in TNDM stock.

19.01.2026 - TNDM Stock was down 5.2%

• The recent decline in TNDM's stock is linked to the ongoing legal concerns and heightened scrutiny stemming from a shareholder lawsuit investigation concerning its t:slim X2 insulin pumps.
• Investor apprehension may be driven by the potential impact of this issue on the company's reputation, product reliability, patient confidence, and disclosure practices, potentially prompting a sell-off of the stock.
• While analysts had optimistic expectations for a narrower loss and increased revenue in the upcoming earnings announcement, uncertainties surrounding the legal inquiry and its financial consequences appear to have outweighed any positive projections, resulting in the downward trend in TNDM's market performance.

03.01.2026 - TNDM Stock was down 7.0%

• TNDM faced a downward trend following the announcement of a voluntary medical device correction for its t:slim X2 insulin pumps.
• The correction addressed a possible speaker-related issue that could disrupt insulin delivery, sparking concerns about the product's reliability.
• A probe by the Rosen Law Firm into potential securities claims exacerbated the negative sentiment surrounding TNDM and led to a significant drop in the stock price.
• Investors reacted strongly to these developments, reflecting apprehensions about the potential impact on Tandem Diabetes Care's financial performance and reputation.

12.01.2026 - TNDM Stock was down 5.1%

• TNDM stock faced a bearish movement possibly linked to ongoing investigations related to potential securities claims by The Rosen Law Firm and a previous stock decline after a voluntary medical device correction announcement.
• The expected loss per share in the upcoming earnings report may have further dampened investor sentiment towards the stock.
• Investor concerns about the reliability and safety of Tandem's insulin pumps, as highlighted in ongoing investigations, likely contributed to selling pressure and uncertainty.
• The convergence of these factors is believed to have influenced the bearish market activity in TNDM stock today.

28.00.2026 - TNDM Stock was down 5.1%

• The improved growth outlook and better-than-expected results in Q4 boosted TNDM initially, but concerns over weak sales volumes, declining ROIC, and restricted access to capital led to a bearish movement.
• The device correction for its insulin pumps and the securities probe raised doubts about the company's risk controls and disclosure practices, impacting investor confidence.
• The investigation into potentially misleading business information following the medical device correction announcement further added to the negative sentiment surrounding TNDM.
• Overall, the combination of regulatory challenges, financial concerns, and legal investigations likely contributed to the bearish movement in TNDM's stock today.

16.00.2026 - TNDM Stock was up 5.3%

• TNDM exceeded revenue expectations in Q3 despite facing a loss, demonstrating resilience amid market challenges.
• Analysts' consensus "Hold" rating on TNDM reflects a cautious outlook on the stock.
• Noteworthy institutional investors such as Assenagon Asset Management S.A. acquiring a considerable stake in TNDM may have fueled the bullish trend, indicating confidence in the company's future.
• AI-generated trading strategies have hinted at potential downside risks, causing some investors to consider this alongside TNDM's positive revenue performance.

10.01.2026 - TNDM Stock was up 5.5%

• The bullish movement in TNDM stock today could be attributed to renewed investor interest following a recent decline and assessment of the company's valuation.
• Despite facing challenges such as the recent voluntary medical device correction for select insulin pumps, investors seem optimistic about Tandem Diabetes Care's future revenue growth and margin expansion potential.
• Analysis suggesting a near-term neutral sentiment might have also contributed to the stock's bullish movement, indicating a potential pause in the previous weakness and presenting favorable risk-reward setups for traders.